Skip to main content
Signal8

Seaport Therapeutics, Inc. (SPTX)

Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Seaport Therapeutics, Inc. Common Stock logo

Seaport Therapeutics, Inc. Common Stock

NASDAQ:SPTXHealthcare
AH+0.00%$21.93
Close$21.93+1.98%
Mkt Cap$1.17B
Float19.35M
O/S53.53M
VOL307K sh
$ Vol$6.8M
RVOL1.30×
Inst Own70.5%
SI19.2%
Dilution
Seaport Therapeutics, Inc. Common Stock logoNASDAQ:SPTXAH$21.93+0.00%
Pipeline2 lead-sponsored trials·2 active0 completed

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
  • Phase 2
    Recruiting

    A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

    SPT-300, Placebo

    Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress

    Enrollment
    360
    Start
    Jun 2025
    Primary Completion
    Mar 2027est.
    Completion
    Mar 2027est.
    NCT07065240
  • Phase 2
    Enrolling by invitation

    An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)

    SPT-300

    Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress

    Enrollment
    360
    Start
    Sep 2025
    Primary Completion
    May 2027est.
    Completion
    May 2027est.
    NCT07161700
Search ClinicalTrials.gov for “Seaport Therapeutics”